Jonathan Badrock
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis.
Journal: Gut microbes
Published: May 16, 2023
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
Journal: Annals of internal medicine
Published: August 08, 2022
REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.
Journal: Contemporary clinical trials
Published: July 25, 2022
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: February 24, 2022
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
Journal: Hepatology (Baltimore, Md.)
Published: January 08, 2021
Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: September 18, 2019
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Journal: The lancet. Gastroenterology & hepatology
Published: March 25, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026